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The objective of this study was to pursue the techniques involving the screening of the human antibody Fab 
fragment against hepatitis B virus surface antigen (HBsAg) and the construction of its disulfide-stabilized Fv 
fragment (dsFv). The phage antibody Fab fragments against HBsAg were screened from the human 
combinatorial immunoglobulin library. Sequence analysis revealed that its heavy chain gene was complete, but 
the light chain gene was lost. To improve the affinity of the antibody by chain shuffling, a human antibody light 
chain gene repertoire was generated by reverse transcriptase-polymerase chain reaction (RT-PCR) from the 
human peripheral blood lymphocytes. A phage antibody sub-library was then constructed by inserting the light 
chain gene repertoire into the phagmid that contained the Fd gene. Five clones with appreciably higher 
absorbance than that of the original clones were obtained, which indicated that the affinity of the light 
chain-shuffled phage antibodies was improved. Then, the mutated genes of dsFv against HBsAg were 
constructed by using PCR-based point mutagenesis method. Purified VH and VL proteins were folded into a 
25-kDa protein, designated as anti-HBsAg dsFv. ELISA and competition ELISA revealed that the dsFv 
maintained the specificity of the Fab by binding to HBsAg, even through with a lower binding activity. These 
results have facilitated the undertaking of further functional analyses of the constructed dsFv, and may therefore 
provide an improved technique for the production and application of dsFvs against HBsAg. 
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Introduction 
The field of recombinant antibodies is a fast 
developing area and has grabbed the attention of a 
large number of researchers [1]. In general, the goal is 
to produce human monoclonal antibodies for disease 
diagnosis and therapy, a goal that was often 
unattainable before. The technology of 
immunoglobulin combinatorial libraries for the 
generation of monoclonal antibodies has undergone 
considerable changes since it was first reported in 
1989. As the phage display technology progresses, the 
phage antibody library has been widely used to isolate 
specific antibody fragments from large antibody gene 
pools. Compared with conventional hybridoma 
technologies, the human phage antibody technology 
has more advantages: 1. The process is efficient and a 
relatively large number of antibodies can be produced; 
2. It has been suggested that it can mimic the key 
features of the humoral immune system in vitro by 
expressing the antibody fragment gene repertoires on 
the surfaces of the bacteriophage (phage display). As a 
result, human antibodies with high affinities can be 
produced without prior immunization or other 
conventional monoclonal antibody generation 
technology; 3. Human antibodies are useful in therapy 
in human. However, it is extremely difficult to make 
human monoclonal antibodies using conventional 
hybridoma technologies. The use of bacteriophage 
display libraries of Fab or scFv antibodies on their 
surfaces has been proven to be efficient for the 
isolation of a diverse set of human monoclonal 
antibodies from immune or nonimmune volunteers 
against a variety of infectious diseases [ 2,3]. In 
comparison to a full-length antibody, Fab fragment 
can be easily expressed in bacterial expression systems 
[4]. Although native unstabilized Fv heterodimers 
have been made from antibodies [ 5] ,  F v s  b y  
themselves are generally unstable because the VH and 
VL domains of the heterodimer can rapidly dissociate 
[6]. This results in drastically reduced binding affinity. Int. J. Biol. Sci. 2008, 4  104
Another disadvantage of Fab fragments is the 
tendency of light chains to form homodimers, which 
are known as Bence Jones proteins [7]. Meanwhile, 
single-chain Fv fragments (scFvs) have a tendency to 
form aggregates and are relatively unstable over time 
[8]. Furthermore, some scFvs show reduced affinity of 
u p  t o  o n e  o r d e r  o f  m a g n i t u d e  a s  c o m p a r e d  t o  t h e  
corresponding Fab fragments [9]. One approach to 
generate stable recombinant Fvs is to connect the VH 
and VL domains by an interdomain disulfide bond 
instead of a linker peptide. Disulfide-stabilized Fvs 
(dsFvs) have resolved most of the problems that are 
associated with scFvs. DsFvs are stable, often show 
full antigen binding activity, and sometimes even 
demonstrate better affinity than scFvs [10].  
During the last two decades, liver transplantation 
for liver diseases related to hepatitis B virus (HBV) 
infection has been successful [11,12]. Administration 
of high doses of HBIG and lamivudine for prophylaxis 
during liver transplantation has reduced the risk of 
the recurrence of HBV and therefore improved the 
survival of the patients undergoing transplants [13]. 
However, the cost of long-term prophylaxis with high 
doses of HBIG is extremely high, and lamivudine may 
lead to the selection of complex mutants [14]. The use 
o f  H B s A g  i s  c o n s i d e r e d  t o  b e  t h e  n e c e s s a r y  
immunoprophylaxis in complex situations such as 
immunosuppressive therapy [15,16].  
In this study, a human immunoglobulin 
combinatorial library was generated by using a phage 
surface display expression system. Phage antibodies 
(Fab fragments) were screened against HBsAg. To 
improve the affinity of the antibody by chain 
shuffling, a human antibody light-chain gene 
repertoire was generated by reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
from human peripheral blood lymphocytes. Then, a 
phage antibody sub-library was constructed by 
inserting the light-chain gene repertoire into the 
phagmid that contained the Fd gene. After 
high-affinity Fab fragment against HBsAg was 
produced, we constructed dsFvs against HBsAg by 
using the PCR-based point mutagenesis method. Fab 
against HBsAg and its dsFv form were expressed in E. 
coli. Such expressions exhibited strong bindings to 
HBsAg. These studies have laid the foundations for 
the production and application of Fab and dsFv 
against HBsAg. 
Materials and Methods 
Materials 
A Fab phage display combinatorial library (1014 
cfu/ml) was previously constructed in our laboratory. 
HBsAg was obtained from the Institute of 
Bioengineering, Academy of Military Medical Sciences 
(Beijing, China). E. coli XL1-Blue and helper phage 
VCSM13 (1012 cfu/ml) were purchased from Promega 
(Madison, WI, USA). The prokaryotic expression 
vector pET-20b (+) and competent E. coli BL21(DE3) 
were purchased from Novagen Inc. (Madison, WI, 
USA). 
Panning of phage library 
Three rounds of biopanning were done as 
previously described [17,18]. After the last round of 
panning, the eluted phages were amplified by 
infection of E. coli XL1-Blue which were then cultured 
in a super-broth (SB) medium plate at 37°C overnight. 
Randomly selected clones were added in 2-ml SB 
medium and maintained at 37°C for 4 h. Fifty 
microliters of the helper phage VCS M13 (1012 cfu/ml) 
was then added separately. The cultures were 
incubated overnight at 37°C, followed by 
centrifugation at 10,800g, 4°C, for 10 min. Twenty five 
microliters of supernatant with an equal volume of 
PBS/T was transferred to the ELISA wells coated with 
the HBsAg antigen (10 μg/ml). The ELISA plate was 
then incubated at 37°C for 2 h and washed 3 times 
with PBS/T. After the addition of enzyme conjugated 
with the antibody (rabbit anti-VCSM13-alkaline 
phosphatase), the ELISA plate was incubated for 
another 1 h at 37°C and washed 3 more times with 
PBS/T. Fifty microliters of the substrate solution was 
then added to each well. The ELISA plate was 
maintained at room temperature and the OD value 
was read after 15 minutes. The absorbance was 
measured as the optical density at 490 nm [19]. 
For inhibition ELISA, positive colony 
phage-containing supernatant (25 μl) mixed with 25 μl 
of PBS/T containing HBsAg (10 μg/ml) was added to 
the ELISA plate wells coated with HBsAg. The control 
was the same phage-containing supernatant (25 μl) 
mixed with 25 μl of PBS/T without HBsAg. ELISA 
was performed as described above. The OD was read 
at 490 nm and its inhibition rate was calculated as 
follows: Inhibition rate (%) = 100 – (OD with 
HBsAg)/(OD without HBsAg). 
Extraction and purification of plasmid cloned with 
phage antibody genes 
XL1-Blue cells infected with positive phages were 
streaked onto a Luria-Bertarni (LB) plate and 
incubated overnight at 37°C. On the next day, single 
colony was selected to inoculate into 2 ml of the LB 
medium containing 50 mg/l of carbenicillin (Car) and 
15 mg/l of tetracycline. The culture was stirred 
overnight at 37°C. The cells were then used for the 
extraction and purification of plasmid by Miniprep Kit 
(50) of QIAGEN (Hamburg, Germany). Int. J. Biol. Sci. 2008, 4  105
By means of agarose gel electrophoresis, we 
determined whether the plasmid contained 
heavy-chain or light-chain genes of the antibody of 
interest after digestion with Spe I/Xho I and Sac I/Xba 
I respectively. 
Heavy-chain gene sequencing 
After digestion with Spe I/Xho I, the plasmid 
pBluescript KS was purified and recovered as 
described previously [20]. The heavy chain was then 
ligated into the plasmid pBluescript KS with T4 DNA 
ligase. XL1-Blue cells transformed with the ligation 
product were streaked on the LB plate containing 
X-gal and IPTG, and were incubated overnight at 
37°C. The white colony identified to be positive by 
PCR was inoculated into the LB medium and then 
incubated overnight at 37°C. To obtain the 
heavy-chain gene sequences, primers from the 5' 
vector sequence (5'-CTCGAGCAGTCTGGGGCTG-3') 
and the CH1 constant region of the antibody 
(5'-CTCGGTGTTGCTGGGCTT-3') were used. The 
heavy-chain gene was sequenced by 
dideoxy-mediated chain-termination method with the 
373A automatic DNA sequence analysis machine 
(Applied Biosystems, Weiterstadt, Germany). 
Construction and biopanning of phage antibody 
sub-library 
A volunteer was immunized with the hepatitis B 
vaccine and 1 ml of blood was obtained. The white 
blood cells were pelleted, and the lymphocytes were 
separated using Histopaque gradients (Sigma, St. 
Louis, MS, USA). The mRNA was extracted from the 
lymphocytes with the mRNA extraction kit 
(Invitrogen, Carlsbad, CA, USA). The first-strand 
cDNA was then synthesized with a primer of oligo 
(dT)15 using a reverse transcriptase first-strand cDNA 
synthesis kit (GIBCO-BRL, Rockville, MD, USA). All 
the light-chain genes (κ and λ) were amplified from 
the cDNA product by PCR using the panel of 5' 
forward primers and 3' reverse primers described 
previously [21]. The variable regions of the κ-light 
chain (Vκ) were amplified using VK1 and VK2, and 
the variable regions of the λ-light chain (Vλ) were 
amplified using VL1 and VL2. The constant regions of 
the κ-light chain (Cκ) were amplified using VK2 and 
CLK, and the constant regions of the λ-light chain (Cλ) 
were amplified using VL2 and CLL. The conditions for 
PCR were as follows: 35 cycles at 90°C for 40 s, 52°C 
for 40 s, and 72°C for 60 s, followed by a final 
extension for 10 min at 72°C. 
The recombination of heavy and light chains was 
performed in a manner similar to that used to 
construct the library. The phagemid pComb3 that 
contains the Fd gene was obtained as mentioned 
above. The shuffling of the immunoglobulin chains 
was performed as described previously [22].  
Expression and renaturation of Fab fragment 
against HBsAg 
Based on the gene sequences of Fab as 
constructed above, the PCR primers were designed by 
using the computer software Primer Premier 5.0, and 
the relative restriction endonuclease sites were 
introduced into the primers for the construction of 
prokaryotic nonfusion expression vectors of pETFd 
and pETL. All of the PCR primers were synthesized 
by Shengong Inc. (Shanghai, China) with the 






and L forward: 
5'-cggaattcattaacattcacctctgttgaagctcttc-3'. The 
underlined sequences represent the restriction sites for 
Nde I and EcoR I. The 5' primer was used to provide 
the cloning site Nde I, and the 3' primer was used to 
provide the cloning site EcoR I. PCR was performed as 
described above, and its product was cloned into 
pGEM-T (Promega, Madison, WI, USA). The 
PCR-amplified Fab genes were cleaved with Nhe I  and 
EcoR I and the purified fragments were then ligated at 
a ratio of 8:1 to cleaved and purified pET-20b(+). The 
ligated phasmids pETFd and pETL were transformed 
into E. coli BL21(DE3). Single colonies were cultured in 
2 ml of LB medium with 50 μg/ml of Car and stirred 
overnight at 37°C. For Fab expression, 50 ml of LB 
with 50 μg/ml of Car was inoculated with 500 μl of 
the overnight culture of the recombinant clone and 
grown at 37°C till the OD600 value was approximately 
0.6. By then, the expression of Fab was induced by 0.4 
mmol/l of IPTG. After 3 h of growth at 37°C, the cells 
were harvested by centrifugation at 6,000 rpm for 10 
min. Ten (10) μl of supernatant was mixed with 10 μl 
of 2 × SDS-sample buffer (5% SDS, 10% glycerol, 
0.002% bromophenol blue, 0.0062 M Tris-HCl, pH 7.0), 
supplemented with 2% mercaptoethanol. The 
extracted Fab fragment protein was renaturated as 
described [23].  
Construction of mutational dsFvs against HBsAg 
The selection of the location of VH and VL 
(H44/L100) has been described [24]. Primers VH5, 
VHM, VH3, VL5 and VL3 used for all the PCR 
analyses are described previously [20]. 
The construction of the dsFv VH mutant gene by 
using the megaprimer PCR method has been 
described [25]. Briefly, VH5 and VHM were used to Int. J. Biol. Sci. 2008, 4  106
amplify the primer VH5-M and then VH5-M and VH3 
were used to amplify the dsFv VH mutant gene. The 
dsFv VL fragment was amplified by using 
conventional PCR using the primers VL5 and VL3. 
The conditions for both PCRs were 30 cycles at 94°C 
for 1 min, 55°C for 1 min, 72°C for 1 min, followed by 
a final extension for 10 min at 72°C. The PCR products 
of the mutated VH and VL genes were cloned into 
plasmid pGEM-T and sequenced using the 
dideoxynucleotide method. 
Expression and renaturation of dsFvs against 
HBsAg 
The plasmids pGEM-VH and pGEM-VL 
constructed as described above were digested by Nhe 
I and EcoR I, and the fragments were inserted into 
pET-20b(+). Then, the positive clones were 
transformed into E. coli BL21(DE3) and the 
expressions of the VH and VL genes were analyzed by 
the SDS-PAGE analysis as described above. The 
dsFv-VH and dsFv-VL proteins, which were extracted 
from the inclusion body, were renaturated and 
identified as described above. 
Comparison of binding activities between Fab 
fragments and dsFvs 
The primers VH1a, PVH3, Vκ1a and PVL3 used 
for the insertion of dsFv genes into pComb3 were 
described previously [20]. VH was amplified using 
VH1a and PVH3. VL was amplified using Vκ1a and 
PVL3 and the VL genes were ligated into the 
phagemid pComb3. Then, the recombinant plasmids 
pComb3, which include the heavy and light chains of 
Fab and dsFv, were transformed into XL1-Blue. The 
preparation of the phage antibodies of Fab and dsFv 
and the ELISA and inhibition ELISA were then 
performed as described above. 
Results 
Isolation of Fab fragment with binding activity 
toward HBsAg 
After three rounds of panning, 30 colonies were 
randomly selected for the collection of Fab. The 
supernatant that contained the Fab was directly 
subjected to the binding activity analysis by means of 
ELISA. The positive ODs (2.1 times or higher than that 
of the negative control) was 69%. Among the 30 clones 
analyzed, 8 clones with OD value 10 times higher than 
that of the negative control demonstrated specific 
binding activities toward HBsAg. The colony Fab-1 
with the highest OD ( OD490 = 0.72 ± 0.02) was 
confirmed by inhibition ELISA. The inhibition rate 
was 86% (OD490 = 0.10 ± 0.01). 
A fragment of approximately 670 bp was 
obtained when the plasmid DNA containing the gene 
of Fab-1 was digested with the restriction enzyme Spe 
I and Xho I (Fig.1). This result suggested that the 
plasmid DNA contained a heavy-chain gene of the 
human phage antibody. This is based on the fact that 
the construction of the human phage antibody 
libraries is on the pComb3 vector in which the 
heavy-chain gene of the human antibody is cloned 
between the restriction enzyme sites of Spe I and Xho I. 
However, the light-chain gene fragment was not 
detected when the positive plasmid DNA was 
digested with the restriction enzymes Sac I and Xba I 
(data not shown). The heavy-chain genes were then 
sequenced and the results of the DNA sequences 
revealed that the heavy chain contained the entire 
variable (VHI) and constant (CHI) regions. When 
compared with the sequences of Genbank [26], the 
variable heavy-chain (VH) gene of Fab-1 was more 
homologous with that of the VHI subgroup (>75%) 
than with that of the other group (<60%). We therefore 
conclude that the heavy-chain gene of Fab-1 belongs 
to the subfamily of the VHI gene. 
 
Fig.1: Restriction enzyme (Spe I and Xho I) digestion of 
plasmid DNA containing the gene of the phage antibody 
against HBsAg. M: DNA molecular weight marker (λ 
DNA/EcoR I + Hind III). 1 and 2: plasmid DNA containing Fd 
gene (Fab-1). 
 
Construction and panning of the light-chain library 
By means of chain shuffling, a light-chain 
sub-library was constructed. Briefly, the 
PCR-amplified κ- and λ-genes were cleaved with Sac I 
and Xba I and the purified fragments were ligated to 
cleaved and purified pComb3. The ligated material 
was then transformed into electrocompetent E. coli 
XL1-Blue. Bacteriophage stock solutions were 
prepared following super infection with VCSM13 
helper phage by culturing overnight at 30°C. Clones 
producing HBsAg-specific Fab were selected and Int. J. Biol. Sci. 2008, 4  107
identified, and sequence analysis of the Fab segments 
was performed as described in the Materials and 
Methods. After 3 rounds of selection, 5 clones with 
absorbance higher than that of phage Fab-1 at 490 nm 
in ELISA were obtained. All the clones contained 
heavy and light chains after enzyme digestion (Fig.2). 
DNA sequencing showed that 3 out of the 5 VL genes 





Fig.2: Restriction enzyme digestion of pComb3 containing 
light- and heavy-chain genes. M: DNA molecular weight 
marker (λ DNA/EcoR I + Hind III). 1: light-chain gene 
digested from pComb3 with Sac I and Xba I. 2: heavy-chain 
gene digested from pComb3 with Spe I and Xho I. 
 
Expression and renaturation of Fab fragment 
protein 
Protein separation was run under reduced 
conditions on 12.5% polyacrylamide gels with a 4% 
stacking gel. The cell pellet was re-suspended in 5 ml 
of 50 mM Tris-HCl (pH 8.0)/2 mM EDTA and 
maintained at 30°C for 15 min after addition of 100 
μg/ml antalzyme/0.5 ml Triton X-100. Clarified 
periplasmic extract was obtained by centrifugation of 
the re-suspended product at 12,000 rpm for 10 min. 
Then, the periplasmic extract was mixed with 50 μl of 
2 × SDS-sample buffer and the pellet was 
re-suspended in 100 μl of 1 × SDS-sample buffer for 
SDS-PAGE analysis. SDS-PAGE analysis revealed that 
the Fd fragment and L chain were expressed in the 
inclusion body form with molecular weights of 27 kDa 
and 25 kDa, respectively (Fig.3). Further more, 
Western blot revealed that both proteins could react 
with the anti-human Fab antibody (Fig.3). This 
indicates that the Fd fragment and L chain belonged to 
human antibodies.   
 
Fig.3: Detection of the Fd fragment and L chain of the 
antibody against HBsAg expressed in E. coli BL21(DE3) by 
SDS-PAGE and Western blot analyses. M: protein molecular 
weight marker; 1: BL21(DE3) cell lysate; 2: cell lysate of 
pETFd -transformed BL21(DE3); 3: cell lysate of pETL 
-transformed BL21(DE3); 4: supernatant from cell lysate of 
pETFd-transformed BL21(DE3); 5: supernatant from cell 
lysate of pETL-transformed BL21(DE3); 6: inclusion body 
extracted from pETFd -transformed BL21(DE3); 7: inclusion 
body extracted from pETL-transformed BL21(DE3); 8 and 9: 
Fd and L chain inclusion body detected by anti-human Fab. 
 
A total of 50-ml culture of E. coli containing 
pETFd or pETL was induced for the protein 
expression under the same condition as mentioned 
above. The inclusion body was isolated and 
solubilized by 8 mol/l urea. Fd and L dissolved in 
urea were mixed in an equal molar concentration. The 
renaturation buffer (0.1 mol/l Tris-HCl, 0.5 mol/l 
L-argine, 8 mmol/l GSSG, and 2 mmol/l EDTA) was 
then added and incubated at 10°C for 24–36 h. After 
that, Fd and L were refolded to yield Fab. Then, 25 μl 
of the folding solution was mixed with 25 μl of 2 × 
SDS-sample buffer and the mixture was detected by 
the SDS-PAGE analysis. In the renaturation buffer, a 
new protein Fab was formed at approximately 52-kDa 
after the Fd fragment and L chain were refolded. This 
result was revealed by the SDS-PAGE analysis as 
shown in Fig.4.   
Construction of dsFv 
The megaprimer fragment (161 bp), which was 
located at the mutant point of position 44 of VH, was 
amplified using the primers VH5 and VHM. The VL 
mutant gene (386 bp), which was found at position 
100 of VL, was amplified using the primers VH5 and 
VHM (Fig.5). The two sites—VH44 (mutation from Gly 
to Cys) and VL100 (mutation from Gln to Cys)—were 
identified by sequencing, and both were successfully Int. J. Biol. Sci. 2008, 4  108
mutated. 
 
Fig.4: Renaturation of Fab fragment proteins. 1: inclusion body 
extracted from cells transformed with pETFd; 2: inclusion 
body extracted from cells transformed with pETL; 3: protein 
molecular weight markers; 4: proteins of L chain and Fd 
fragment before renaturation; 5: renatured products of L chain 




Fig.5: Electrophoresis of the PCR products of the megaprimer, 
VH, and VL. M: PCR markers, 1: megaprimer, 2: PCR product of 
VH, 3: PCR product of VL. 
 
Expression and renaturation of dsFv 
SDS-PAGE analysis revealed that the dsFv was 
expressed as an inclusion body protein (25 kDa) 
(Fig.6). The protein could be reduced to VH and VL 
after treatment with β-mercaptoethanol or boiling for 
5 min (Fig.7).   
 
Fig.6: SDS-PAGE analysis of the expressed VH and VL genes of 
dsFv against HBsAg in E. coli. M: protein molecular weight 
markers; 1: total fractions of cells expressing VH gene; 2: total 
fractions of cells expressing VL gene; 3: soluble fractions of 
cells expressing VH gene; 4: soluble fractions of cells expressing 
VL gene; 5: insoluble fractions of cells expressing VH gene; 6: 




Fig.7: SDS-PAGE analysis of VH and VL proteins folding into 
dsFv. M: protein molecular weight markers; 1: dsFv boiled for 
5 min; 2: dsFv boiled for 10 min; 3: dsFv treated at 37°C for 15 
min; 4: VH and VL proteins folding into dsFv; 5: VH and VL 
proteins diluted into refolding buffer; 6: VL protein; 7: dsFv 
incubated with β-mercaptoethanol; 8: VH protein. 
 
Comparison of antigen binding activities between 
Fab fragment and dsFv by ELISA and inhibition 
ELISA 
ELISA and competition/inhibition ELISA were 
performed as described in Materials and Methods. 
Results revealed that while dsFv showed lower 
binding activity to HBsAg (0.56±0.08) than that of Fab 
(1.22±0.13), it maintained the specificity of the Fab to 
bind to HBsAg (Table 1).   Int. J. Biol. Sci. 2008, 4  109
Table 1 ELISA and inhibition ELISA 
samples ELISA(X±SD)  inhibition 
ELISA(X±SD) 
inhibition(%) 
Fab 1.22±0.13 0.42±0.14  65.6 
dsFv 0.56±0.08  0.16±0.11  71.4 
positive 
control 
1.65±0.09 -  - 
negative 
control 
0.08±0.16 -  - 
Discussion  
Human-engineered antibodies are the third 
generation of antibodies which have potential 
therapeutic applications in human diseases. Some of 
the engineered antibodies have been approved by 
FDA in the USA for clinical uses. The phage antibody 
library technology makes possible not only the 
production of large numbers of human antibodies that 
are difficult to obtain using the hybridoma method 
but also the screening of many specific antibodies 
against various antigens. In this regard, both pIII and 
pVIII phage display formats have been used for the 
construction of various libraries. There was also report 
showing that pVII and pIX could be used to 
individually display fusion proteins, notably the VH 
and VL of the antibody Fv fragment [27]. Large and 
nonimmune or ‘‘naïve’’ antibody-phage libraries 
displayed on pIII have proven to be a method to 
readily isolate high-affinity and specific human 
antibodies against a variety of target antigens. 
Although Human antibody Fab fragments that bind to 
HBsAg were generated by using a recombinant phage 
surface-display expression system [28], a significant 
disadvantage of Fab fragments is the formation of 
light chain homodimers [7]. In this study, we 
successfully constructed pIII phage antibody libraries 
using semi-nested PCR, remarkably increased the size 
of the libraries, and screened the phage antibody Fab 
fragments that can bind HBsAg specifically from the 
antibody libraries. Importantly, the more stable dsFv 
fragment against HBsAg was constructed from its Fab 
form by “chain shuffling” technique. This work thus 
represents significant improvements over the 
techniques described previously by the other 
laboratories [29]. The results of restriction enzyme 
digestion revealed that this specific antibody 
contained a heavy chain gene. Sequence analysis 
showed that the heavy chain comprised the entire 
variable (VH1) and constant (CH1) regions. Although 
the restriction enzyme digestion demonstrated that its 
light chain gene was lost, the phage antibody with the 
entire heavy chain gene exhibited definite binding 
activity to HBsAg. Generally, it is considered that the 
variable heavy chain region of the antibody plays a 
leading role, while the variable light chain region 
plays a subordinate role in the binding process of 
antibody to antigen. It is possible that the antibody, 
which undergoes significant conformational changes, 
ameliorates its binding to the antigen (“induced fit” 
antibody). Therefore, we rescreened the light chain 
gene while the heavy chain gene was fixed to imitate 
the antibody maturing procedure in vitro in order to 
increase the antigen binding affinity by the “chain 
shuffling” method. Fortunately, we screened the light 
chain gene by using this method and therefore 
obtained the genes of the entire phage antibody (Fab 
fragment) against HBsAg. This antibody significantly 
increased the binding activity to HBsAg. The VL and 
VH proteins were expressed and refolded into active 
molecules  in vitro. Furthermore, we successfully 
applied this technology to the expression of dsFvs 
against HBsAg.   
DsFvs (disulfide-stabilized Fvs) are significantly 
more stable in human serum and under various 
conditions. Therefore, we constructed the mutated 
genes of dsFvs against HBsAg by using the PCR-based 
point mutagenesis method. The design of the disulfide 
connection was made by employing molecular 
modeling techniques. Previous studies [ 30 ] have 
identified two positions located in the interface 
between VH and VL: the best locations for disulfide 
stabilization are position 44 in framework region 2 
(FR2) of VH and position 100 of FR4 of VL or position 
105 of FR4 in VH and position 43 of PR2 in VL. The 
mutated genes of VH and VL were cloned into plasmid 
pET-20b and sequenced with the dideoxynucleotide 
method. The results showed that the cysteines were 
successfully introduced at position 44aa of VH and 
position 100aa of VL. The recombinant proteins of VH 
and VL were separately expressed in E. coli BL21(DE3). 
The VH and VL inclusion bodies were solubilized and 
combined in equal molar ratios in the refolding 
solution. Then, VH and VL were folded into a 25-kDa 
protein, designated as anti-HBsAg dsFv, which 
exhibited strong binding toward HBsAg. 
ELISA and competition/inhibition ELISA in this 
study indicated that the constructed dsFv maintained 
the specificity of Fab, but it exhibited lower binding 
activity toward HBsAg than Fab. Reiter et al [31] 
reported that each Fv is influenced differently with 
regard to its binding affinity to antigens after disulfide 
stabilization. While the antigen specificity may not be 
altered, disulfide stabilization can increase or decrease 
the binding affinity of individual Fvs. However, the 
l o s s  o f  b i n d i n g  a f f i n i t y  can be compensated by the 
significantly improved stability of dsFvs [31]. 
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